COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2023. For the period, the company expects net sales of JPY 813,500 million, operating profit of JPY 30,000 million, profit attributable to owners of parent JPY 23,200 million and basic earnings per share of JPY 585.87.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14,390 JPY | -0.79% | -0.28% | -11.64% |
Apr. 12 | Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months | MT |
Apr. 12 | COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.64% | 3.62B | |
-0.09% | 3.36B | |
-23.44% | 3.06B | |
+7.56% | 2.67B | |
+7.46% | 2.59B | |
-9.26% | 1.75B | |
+9.30% | 1.35B | |
-20.60% | 957M | |
-38.42% | 704M | |
-1.85% | 370M |
- Stock Market
- Equities
- 3349 Stock
- News COSMOS Pharmaceutical Corporation
- COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2023